Intercept Pharmaceuticals (ICPT) PT Lowered to $115 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Intercept Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update
August 2, 2018 7:05 AM EDTWorldwide Ocaliva net sales of $43.2 million in the second quarter of 2018Leading Phase 3 NASH program continues to advance: REGENERATE trial in NASH patients with advanced liver fibrosis expected to report data in the first half of 2019
Conference call scheduled for 8:30 a.m. ET today
NEW YORK, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver... More
